The Next Frontier in Immunotherapy for Multiple Myeloma: What Will BCMA Targeting Mean for Our Relapsed/Refractory Patients? Video Activity
VirtualKey learning objectives:
∙ Explain the mechanism of action of BCMA-targeted strategies for the treatment of relapsed/refractory multiple myeloma (RRMM)
∙ Evaluate the clinical evidence with BCMA-targeted approaches for the treatment of RRMM
∙ Discuss practical considerations, including key differences between BCMA-targeted treatments, that may inform their use in RRMM